Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. covers events occurring between May 10, 2019, and May 22, 2019, with the report dated May 22, 2019. The filing details unregistered sales of equity securities and the issuance of convertible promissory notes.
Key Financial Metrics
- Debt Conversion: The Company issued 1,358,903 shares of common stock to settle outstanding indebtedness totaling $269,230 (inclusive of accrued interest).
- New Debt Issuance: The Company issued convertible promissory notes with an aggregate principal amount of $257,500.
- Cash Proceeds: The new notes generated aggregate cash proceeds of $245,000.
- Interest Rate: The new notes bear interest at 12% per annum.
- Maturity: The notes have original maturity dates in May 2020.
Material Changes
The filing reports two distinct capital structure changes:
- Reduction of debt liabilities through the conversion of $269,230 in indebtedness into equity.
- Increase in debt liabilities via the issuance of $257,500 in new convertible notes, resulting in a net cash inflow of $245,000.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the securities' terms. The securities were issued under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and exchanges with existing security holders. The Company believes all investors are accredited.
Investor Verification Checklist
- Verify the exact number of shares issued for debt conversion (1,358,903) and the resulting dilution impact.
- Confirm the conversion price terms for the new notes ($1.00 or $2.00 fixed for six months, then 58% of fair value).
- Review the Company's liquidity position following the $245,000 cash infusion.
- Check subsequent filings for any changes in the conversion status of the May 2019 notes.